ArticleClinical transplantation2026
Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe effects of induction therapy with the anti-CD52 monoclonal antibody alemtuzumab on age-specific outcomes following kidney transplantation (KT) remain inadequately studied. This study aimed to analyze the comparative safety and efficacy of single-dose alemtuzumab induction in deceased donor (DD) KT recipients according to different recipient age groups.
methodsSingle-center retrospective nonrandomized cohort review of DDKT recipients stratified by age (30-49/50-69/
resultsFrom September 2012 to December 2018, 723 DDKTs were performed with alemtuzumab induction. Donor age (33.1 ± 15.7 vs. 47.3 ± 16.0 vs. 53.3 ± 13.4 years; p < 0.001) and kidney donor profile index (KDPI, 46.5 ± 25.1 vs. 65.5 ± 23.8 vs. 74.4 ± 20.5%; p < 0.001) increased with increasing recipient age groups. Overall patient (p < 0.001) and graft (p < 0.001) but not death-censored graft survival (p = 0.6) rates decreased with increasing recipient age strata. Rates of delayed graft function, biopsy-proven acute rejection, and infectious complications at 1-year post-transplant were comparable amongst groups.
conclusionIn DDKT recipients, alemtuzumab induction does not appear to confer excess risk of graft failure, acute rejection, or short-term infectious complications in older patients relative to younger counterparts in the setting of triple maintenance immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.